MGMT PROMOTER METHYLATION STATUS INDEPENDENTLY PREDICTS PROGRESSION-FREE SURVIVAL IN NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT plus PCV IN HIGH-RISK LOW-GRADE GLIOMAS Conference

Bell, EH, Zhang, P, Aldape, K et al. (2017). MGMT PROMOTER METHYLATION STATUS INDEPENDENTLY PREDICTS PROGRESSION-FREE SURVIVAL IN NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT plus PCV IN HIGH-RISK LOW-GRADE GLIOMAS . NEURO-ONCOLOGY, 19 2-3.

International Collaboration

cited authors

  • Bell, EH; Zhang, P; Aldape, K; McElroy, J; Mehta, M; Fleming, J; Liu, Z; Coons, S; Johnson, D; Chakravarti, A

sustainable development goals

authors

date/time interval

  • May 4, 2017 -

publication date

  • May 1, 2017

webpage

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • Zurich, SWITZERLAND

Conference

  • 5th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology-Societies (WFNOS)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 2

end page

  • 3

volume

  • 19